Invivoscribe Backs CERo Therapeutics in Advancing Innovative AML Immunotherapy

Invivoscribe’s Support to CERo Therapeutics

Image: News Hub Medianet

Announcement

Invivoscribe Inc., a leader in measurable residual disease (MRD) testing and accurate diagnostics, is joining hands with and appreciating CERo Therapeutics Holdings Inc.’s approach to innovative immunotherapy that promises an advancement in engineered T cell therapeutics that will highlight the presence of phagocytic mechanisms. It’s a collaboration involving customization of multiparametric flow cytometry (MFC) services in LabPMM, which is an Invivoscribe-referred laboratory. With this partnership, LabPMM will introduce the MFC AML MRD assay that will contribute to CERo’s clinical trial. The clinical trial of CER-1236 focuses on acute myeloid leukemia (AML) in patients suffering from any refractory/relapse with MRD or a newly diagnosed TP53-mutated MDS/AML.

This supportive partnership was an effort to advance CER-1236. CER-1236 has received FDA Orphan drug designation for the treatment of AML. The designation of CER-1236 showcases the need for compiled diagnostic support for personalized immunotherapies is a sign of Invivoscribe’s commitment.

What is AML?

AML is a severe condition of blood cancer featuring the accumulation of abnormal myeloid cells found in blood and bone marrow, which interrupts normal hematopoiesis. The treatment for AML is quite complicated because of the risk of relapse and genetic heterogeneity. The chimeric engulfment receptor T-cells (CER-T) and chimeric antigen receptor T-cells (CAR-T) therapies consist of evaluating the patient’s T-cells to address and attack cancer cells, have been an effective therapy in various other hematologic malignancies, and have been considered for AML. These therapies are driven by the patient’s cells, so it doesn’t truly confirm the use of the leukemic final therapeutic product. It needs precision and awareness to understand the sensitivity to validate assays.

LabPMM CAP/CLIA has validated the AML MRD MFC assay, which was introduced to calculate residual leukemic cells in patients under treatment. The initiative further implements customization to serve two complex needs in CERo’s drug development program. The first need is the assessment of the manufactured T-cells product via detecting the possibility of residual AML blast before infusion, and another is the evaluation of therapeutic response to CER-1236 during a trial.

Views and Statements

Chief Development Officer of CERo, Phd Kristen Pierce said, “Invivoscribe has played a crucial role in executing the clinical trial. The expertise and technology have served our clinical advancement. It will help us to purify our investigational product. We are pleased by the benefits through this collaboration as the trial is in process, and we expect a positive therapeutic response.”